Social IV has invested EUR 1.5 million in TheSocialMedwork to enhance global access to affordable medications for patients with severe health conditions.

Target Information

TheSocialMedwork (TSM) is a pioneering company focused on assisting patients with life-threatening and debilitating diseases in accessing the latest medications at the most affordable prices. By bridging the gap between patients and advanced treatment options available in developed markets such as the USA, EU, and Japan, TSM has made a significant impact on the lives of patients across more than 70 countries around the world. TSM stands out for its patient-centric approach, emphasizing the importance of timely and affordable access to essential medicines for those in urgent need.

Through its innovative and scalable business model, TSM aims to address the challenges of medication inaccessibility and exorbitant pricing in the global pharmaceutical market. With a remarkable team that includes individuals who have personal experiences with severe illnesses, TSM is on a relentless quest to inform patients, their families, and healthcare providers about current health management options while ensuring affordability and availability.

Industry Overview

The pharmaceutical industry has faced numerous challenges globally, and the situation is particularly dire in many regions where access to new treatments is limited. Many patients remain unaware of the latest therapies available in developed nations, resulting in